Survodutide
A novel dual GLP-1/glucagon receptor agonist that regulates appetite and increases energy expenditure. Also shows significant benefits for liver health.
Key Benefits for Med Spas
Clinical Evidence
"Phase II trial: nearly 19% weight loss. 62% of MASH patients showed improvement."
Administration
Available Options
Wholesale pricing. Contact us for volume discounts and custom orders.
Quick Facts
Related Products
View allSemaglutide
A GLP-1 receptor agonist that mimics the naturally occurring GLP-1 hormone. Stimulates insulin secretion, suppresses appetite, and slows gastric emptying for powerful weight management.
Tirzepatide
A dual GIP/GLP-1 receptor agonist that activates both incretin receptors for superior weight loss. Regulates blood sugar, suppresses appetite, and increases feelings of fullness.
Retatrutide
An investigational triple-agonist peptide targeting GIP, GLP-1, and glucagon receptors. Regulates appetite, increases energy expenditure, and improves metabolic function for extreme weight loss.